Cargando…

Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion

Background: While autologous bone grafts remain the gold standard for spinal fusion procedures, harvesting autologous bone is associated with significant complications, including donor site infection, hematomas, increased operative time, and prolonged pain. Cellular bone allograft (CBA) presents an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wind, Joshua, Park, Daniel, Lansford, Todd, Nunley, Pierce, Peppers, Timothy, Russo, Anthony, Hassanzadeh, Hamid, Sembrano, Jonathan N., Yoo, Jung, Sales, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680433/
https://www.ncbi.nlm.nih.gov/pubmed/36412692
http://dx.doi.org/10.3390/neurolint14040070
_version_ 1784834416647864320
author Wind, Joshua
Park, Daniel
Lansford, Todd
Nunley, Pierce
Peppers, Timothy
Russo, Anthony
Hassanzadeh, Hamid
Sembrano, Jonathan N.
Yoo, Jung
Sales, Jonathan
author_facet Wind, Joshua
Park, Daniel
Lansford, Todd
Nunley, Pierce
Peppers, Timothy
Russo, Anthony
Hassanzadeh, Hamid
Sembrano, Jonathan N.
Yoo, Jung
Sales, Jonathan
author_sort Wind, Joshua
collection PubMed
description Background: While autologous bone grafts remain the gold standard for spinal fusion procedures, harvesting autologous bone is associated with significant complications, including donor site infection, hematomas, increased operative time, and prolonged pain. Cellular bone allograft (CBA) presents an alternative to autologous bone harvesting, with a favorable efficacy and safety profile. The current study further investigates CBA as an adjunct to lumbar spinal fusion procedures. Methods: A prospective, multicenter, open-label clinical study was conducted in subjects undergoing lumbar spinal fusion with CBA (NCT 02969616). Radiographic fusion status was assessed by an independent review of dynamic radiographs and CT scans. Clinical outcome measures included the Oswestry Disability Index (ODI) and visual analogue scale (VAS) for back and leg pain. Adverse-event reporting was conducted throughout 12 months of follow-up. Available subject data at 12 months were analyzed. Results: A total of 274 subjects were enrolled into the study, with available data from 201 subjects (73.3%) who completed 12 months of postoperative radiographic and clinical evaluation at the time of analysis. Subjects had a mean age of 60.2 ± 11.5 years. A higher number of women (n = 124, 61.7%) than men (n = 77, 38.3%) were enrolled, with a collective mean BMI of 30.6 + 6.5 kg/m(2) (range 18.0–51.4). At month 12, successful fusion was achieved in 90.5% of subjects. A significant (p < 0.001) improvement in ODI, VAS-back, and VAS-leg clinical outcomes was also observed compared to baseline scores. One adverse event related to CBA (postoperative radiculopathy) was reported, with surgical exploration demonstrating interbody extrusion of graft material. This subject reported successful fusion at month 12. Conclusions: CBA represents a viable substitute for harvesting of autograft alone with a high rate of successful fusion and significant improvements in subject-reported outcomes, such as pain and disability. Positive benefit was observed in subjects reporting single and multiple risk factors for pseudoarthrosis.
format Online
Article
Text
id pubmed-9680433
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96804332022-11-23 Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion Wind, Joshua Park, Daniel Lansford, Todd Nunley, Pierce Peppers, Timothy Russo, Anthony Hassanzadeh, Hamid Sembrano, Jonathan N. Yoo, Jung Sales, Jonathan Neurol Int Article Background: While autologous bone grafts remain the gold standard for spinal fusion procedures, harvesting autologous bone is associated with significant complications, including donor site infection, hematomas, increased operative time, and prolonged pain. Cellular bone allograft (CBA) presents an alternative to autologous bone harvesting, with a favorable efficacy and safety profile. The current study further investigates CBA as an adjunct to lumbar spinal fusion procedures. Methods: A prospective, multicenter, open-label clinical study was conducted in subjects undergoing lumbar spinal fusion with CBA (NCT 02969616). Radiographic fusion status was assessed by an independent review of dynamic radiographs and CT scans. Clinical outcome measures included the Oswestry Disability Index (ODI) and visual analogue scale (VAS) for back and leg pain. Adverse-event reporting was conducted throughout 12 months of follow-up. Available subject data at 12 months were analyzed. Results: A total of 274 subjects were enrolled into the study, with available data from 201 subjects (73.3%) who completed 12 months of postoperative radiographic and clinical evaluation at the time of analysis. Subjects had a mean age of 60.2 ± 11.5 years. A higher number of women (n = 124, 61.7%) than men (n = 77, 38.3%) were enrolled, with a collective mean BMI of 30.6 + 6.5 kg/m(2) (range 18.0–51.4). At month 12, successful fusion was achieved in 90.5% of subjects. A significant (p < 0.001) improvement in ODI, VAS-back, and VAS-leg clinical outcomes was also observed compared to baseline scores. One adverse event related to CBA (postoperative radiculopathy) was reported, with surgical exploration demonstrating interbody extrusion of graft material. This subject reported successful fusion at month 12. Conclusions: CBA represents a viable substitute for harvesting of autograft alone with a high rate of successful fusion and significant improvements in subject-reported outcomes, such as pain and disability. Positive benefit was observed in subjects reporting single and multiple risk factors for pseudoarthrosis. MDPI 2022-10-26 /pmc/articles/PMC9680433/ /pubmed/36412692 http://dx.doi.org/10.3390/neurolint14040070 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wind, Joshua
Park, Daniel
Lansford, Todd
Nunley, Pierce
Peppers, Timothy
Russo, Anthony
Hassanzadeh, Hamid
Sembrano, Jonathan N.
Yoo, Jung
Sales, Jonathan
Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion
title Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion
title_full Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion
title_fullStr Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion
title_full_unstemmed Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion
title_short Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion
title_sort twelve-month results from a prospective clinical study evaluating the efficacy and safety of cellular bone allograft in subjects undergoing lumbar spinal fusion
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680433/
https://www.ncbi.nlm.nih.gov/pubmed/36412692
http://dx.doi.org/10.3390/neurolint14040070
work_keys_str_mv AT windjoshua twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion
AT parkdaniel twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion
AT lansfordtodd twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion
AT nunleypierce twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion
AT pepperstimothy twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion
AT russoanthony twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion
AT hassanzadehhamid twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion
AT sembranojonathann twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion
AT yoojung twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion
AT salesjonathan twelvemonthresultsfromaprospectiveclinicalstudyevaluatingtheefficacyandsafetyofcellularboneallograftinsubjectsundergoinglumbarspinalfusion